Washington, DC, July 18-23 2015
The Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) is the primary neurocognitive outcome measure in many clinical trials for mild-moderate Alzheimer’s disease (AD). Despite wide use, variations in administration and scoring are well-documented (1), and may reduce reliability and sensitivity of the measure (2). Clinical trials devote considerable effort and resources to rater training and quality assurance of ADAS-Cog endpoints. To examine the efficacy of these efforts in improving ADAS-Cog reliability, we evaluated the impact of central data review on ADAS-Cog test-retest reliability in an ongoing, multicenter, placebo-controlled treatment trial (NCT01852110).